Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27641128 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL28123586 | 0.75 | KDM4E (0.41) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL20305131 | 0.75 | HDAC6 (0.41) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL20305077 | 0.75 | HDAC6 (0.41) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL27794195 | 0.72 | KDM4E (0.44) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL9182449 | 0.72 | KDM4E (0.46) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL27944268 | 0.72 | HSP90AA1 (0.41) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL3290197 | 0.71 | KDM4E (0.41) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL9185978 | 0.71 | KDM4E (0.43) | KDM4EALDH1A1HPGDADRA1AHSD17B10 | |
| SCHEMBL10469883 | 0.71 | KDM4E (0.43) | KDM4EALDH1A1HPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318700-B2 | Lung-targeted drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-17 | — | — | US | disclosed |
| US-8101745-B2 | Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| US-5877166-A | HERPES VIRUS | SRI INTERNATIONAL (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1997041133-A1 | ENANTIOMERICALLY PURE 2-AMINOPURINE PHOSPHONATE NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1997-11-06 | — | — | WO | disclosed |
| WO-1997041133-A1 | ENANTIOMERICALLY PURE 2-AMINOPURINE PHOSPHONATE NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1997-11-06 | — | — | WO | disclosed |
| WO-1997041133-A1 | ENANTIOMERICALLY PURE 2-AMINOPURINE PHOSPHONATE NUCLEOTIDE ANALOGS AS ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221061-A1 | Lung-Targeted Drugs | DGKG, GK, PHOSPHO1 | KDM4E 1694/4885ALDH1A1 4007/4885HPGD 1715/4885 |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | DGKG, GK, PHOSPHO1 | KDM4E 1694/4885ALDH1A1 4007/4885HPGD 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.